Key facts
- This page summarizes James B. Tananbaum's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Oct 2021, 16:15.
James B. Tananbaum - 04 Oct 2021 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- IRON
- Reported as of
- 04 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Oct 2021, 16:15:57 UTC
- Prior SEC filing
- 14 Jun 2021
- Next SEC filing
- 23 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Meyenburg, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James B. Tananbaum filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 06 Oct 2021.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRON
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,500,000
- Date
- 04 Oct 2021
- Ownership
- See footnote
- Footnotes
- F2, F3
IRON
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,928,750
- Date
- 04 Oct 2021
- Ownership
- See footnote
- Footnotes
- F2, F3
IRON
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 411,500
- Date
- 04 Oct 2021
- Ownership
- See footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRON
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +17,245
- Change %
- Price
- $0.000000
- Shares after
- 17,245
- Date
- 04 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,245
- Exercise price
- $3.80
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.
Footnote F2
These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares.
Footnote F3
(continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.